Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Acrivon Therapeutics, Inc. - Common Stock (NQ: ACRV )

6.600 -0.360 (-5.17%)
Streaming Delayed Price Updated: 12:02 PM EST, Nov 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Acrivon Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific Conferences - Human Proteome Organization World Congress and EORTC-NCI-AACR Symposium
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics: Q4 Earnings Insights
Via Benzinga
Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics to Present at the Cantor Global Healthcare Conference
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics to Host Virtual Investor Event to Review Positive Phase 2 Clinical Data of ACR-368 Presented at ESMO and Pipeline Progress, Including Clinical Candidate ACR-2316
From Acrivon Therapeutics, Inc
Via GlobeNewswire
ACRV Stock Earnings: Acrivon Therapeutics Beats EPS for Q2 2024
ACRV stock results show that Acrivon Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Acrivon Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference
From Acrivon Therapeutics, Inc
Via GlobeNewswire
ACRV Stock Earnings: Acrivon Therapeutics Beats EPS for Q1 2024
ACRV stock results show that Acrivon Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are a great way to start Thursday as we check out all of the hottest news moving shares this morning! 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Crude Oil Down Over 1%; Cognyte Software Shares Plummet
U.S. stocks traded lower toward the end of trading, with the S&P 500 falling around 0.4% on Tuesday. The Dow traded down 0.46% to 38,713.72 while the NASDAQ fell 0.24% to 16,215.32. The S&P 500 also... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Tilray Brands, Inc. (NASDAQ: TLRY) fell sharply during Tuesday’s session after the company missed third-quarter estimates and said it no longer expects to generate positive adjusted free 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Dow Dips 150 Points; Laser Photonics Shares Spike Higher
U.S. stocks traded lower midway through trading, with the Dow Jones index falling around 150 points on Tuesday. The Dow traded down 0.39% to 38,742.12 while the NASDAQ fell 0.16% to 16,227.77. The S&P... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Rail Vision (RVSN) Stock Up 17% Today?
Rail Vision stock is taking off on Tuesday as RVSN investors celebrate an order for its AI Switch Yard System from a Class 1 company. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
ACRV Stock Jumps 55% as Acrivon Therapeutics Gets $130 Million Boost
Acrivon Therapeutics stock is up on Tuesday with heavy trading of ACRV shares alongside $130 million in new funding today. 
Via InvestorPlace
Acrivon Therapeutics Stock Is Soaring Tuesday: What's Going On?
Acrivon Therapeutics has entered into a securities purchase agreement to issue and sell 8.235 million shares of its common stock at a price of $8.50 per share, as well as pre-funded warrants to... 
Via Benzinga
Dow Gains Over 50 Points; Neogen Posts Downbeat Earnings
U.S. stocks traded higher this morning, with the Dow Jones index gaining over 50 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.20% to 38,972.32 while the NASDAQ rose... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Acrivon Therapeutics Announces $130 Million Private Placement Financing
From Acrivon Therapeutics, Inc
Via GlobeNewswire
ACRV Stock Earnings: Acrivon Therapeutics Misses EPS for Q4 2023
ACRV stock results show that Acrivon Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
From Acrivon Therapeutics, Inc
Via GlobeNewswire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.